Cardiovascular risk assessment for patients with lipid disorders in emergency care

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders (EMERALD) aims to improve preventive cardiovascular care for emergency department patients evaluated for acute coronary syndrome. This intervention includes ordering a lipid panel, calculating atherosclerotic cardiovascular disease risk, prescribing statins, providing lifestyle counseling, and ensuring follow-up care. The study will compare the effectiveness of this protocolized approach against usual care in reducing LDL cholesterol levels among at-risk patients. A total of 130 patients will be randomized to either the EMERALD intervention or standard care to assess outcomes at 30 and 180 days.

Why it matters

Who can join: the full rules

Inclusion Criteria

1. Evaluation for Acute Coronary Syndrome
2. Age 40-75 Years
3. 10-year Atherosclerotic Cardiovascular Disease (ASCVD) Risk ≥7.5% or Known Diabetes or

Known ASCVD:

1. Myocardial Infarction
2. Unstable Angina
3. Percutaneous Coronary Intervention
4. Coronary Artery Bypass Graft
5. Stroke
6. Transient Ischemic Attack
7. Peripheral Artery Disease

Exclusion Criteria

1. ST-Segment Elevation Myocardial Infarction (STEMI) Activation
2. ST Depression \>1 mm in Contiguous Leads
3. On a Lipid Lowering Agent (Statin, PCSK9 Inhibitor, Bempedoic Acid, Ezetimibe, Inclisiran, etc.)
4. Inability to Return for 30-day Follow-up
5. Unstable Vitals (Systolic blood pressure \<90, HR \>120 or \<50, oxygen saturation \<90%)
6. Statin Intolerance
7. Any Resulted High-Sensitivity Troponin I ≥100 ng/L
8. End-stage renal disease (ESRD) and/or glomerular filtration rate (GFR) \<30 mL/min/1.73 m2
9. Liver Cirrhosis
10. Pregnancy
11. Anticipated Hospitalization
12. Life Expectancy \<1 Year
13. Transfer from Another Hospital
14. Prisoner
15. Non-English Speaking

Where it's running

• Wake Forest University Health Sciences
  Winston-Salem, North Carolina, United States Recruiting

Study contacts

• Principal investigator: Nick Ashburn — Nicklaus.Ashburn@wfusm.edu
• Study coordinator: Lauren Koehler
• Email: Lauren.Koehler@Advocatehealth.org
• Phone: 336-716-4646

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Moderate-Intensity Statin + Ezetimibe vs High-Intensity Statin in CKD with ASCVD

  In adults with chronic kidney disease and established cardiovascular disease, this study tests whether a moderate-intensity statin plus ezetimibe can match the benefits of a high-intensity statin alone over three years.

  Recruiting Yonsei University · Seoul · NCT07524101

• Guideline-based lipid lowering approach in Asia-Pacific patients

  This study tests if a special cholesterol management plan helps people in the hospital for a heart attack feel better compared to standard care.

  Recruiting at 11 sites Monash University · Wollongong, New South Wales and 21 other locations · NCT05325034

• VERVE-102 for adults with or at high risk for heart disease

  This study tests whether VERVE-102 can lower bad cholesterol (LDL-C) compared with a placebo in adults with plaque buildup or high risk for it.

  Recruiting Phase 2 Verve Therapeutics, Inc. · DeSoto, Texas · NCT07839936

• Colchicine for preventing cardiovascular disease in adults with type 2 diabetes

  A 24-week study will test whether low-dose colchicine can help protect blood vessels in adults with type 2 diabetes who have not yet developed artery disease, compared with a placebo.

  Recruiting Phase 2 Tan Tock Seng Hospital · Singapore, Singapore · NCT07837934

• See if Lepodisiran lowers coronary plaque in people with high Lp(a) and heart disease risk

  This study tests whether lepodisiran can reduce heart-artery plaque in adults with high Lp(a) compared to placebo.

  Recruiting at 53 sites Phase 3 Eli Lilly and Company · La Jolla, California and 56 other locations · NCT07613294

• Single versus dual antiplatelet therapy after drug-coated balloon angioplasty in elderly or high-bleeding-risk patients

  This study tests whether taking one antiplatelet medicine is as safe and causes less bleeding than taking two medicines for people aged 75 or older, or adults at high bleeding risk, after drug-coated balloon angioplasty for coronary artery disease.

  Recruiting Fondazione Ricerca e Innovazione Cardiovascolare ETS · Milan, MI · NCT06535568

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.